Welcome to our dedicated page for 89Bio SEC filings (Ticker: ETNB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, drug safety tables, and future financing risks—89bio, Inc.’s SEC filings pack dense science into legal language. When the company reports a pivotal MASH study update or details fresh equity raises, the information is buried across 8-K exhibits, 10-Q footnotes, and proxy tables. Tracking 89Bio insider trading Form 4 transactions or gauging cash runway in the latest annual report can feel like decoding a lab notebook.
Stock Titan’s AI-powered platform turns those pages into plain English. Our engine flags every ETNB Form 4 insider transactions real-time, offers a 60-second digest for each 89Bio quarterly earnings report 10-Q filing, and links clinical milestones directly to financial impact. Need the 89Bio annual report 10-K simplified? One click delivers key pipeline timelines, R&D spend, and dilution scenarios. The tool even provides 89Bio 8-K material events explained and keeps 89Bio SEC filings explained simply for fast reference.
Whether you’re modeling valuation or monitoring governance, you’ll find what matters fast:
- Understanding 89Bio SEC documents with AI—concise summaries with source links
- 89Bio earnings report filing analysis that highlights trial costs vs. cash reserves
- 89Bio executive stock transactions Form 4 alerts before market open
- 89Bio proxy statement executive compensation tables mapped to performance milestones
No more Ctrl-F across hundreds of pages; our real-time feed and expert context keep investors focused on decisions, not document hunts.
Amaze Holdings, Inc. (NYSE American: AMZE), formerly Fresh Vine Wine, filed an 8-K dated 11 July 2025 to disclose a new consulting agreement and related unregistered share issuance.
- Consulting Agreement: Signed 11 July 2025 with DNA Holdings Venture Inc. (Puerto Rico) for a 12-month term, auto-renewable for another 12 months unless cancelled on 30-days notice.
- Scope of Services: Crypto strategy & token architecture, e-commerce/Web3 integration, cross-border currency solutions, credibility/visibility support and market-making for the Company’s planned Token Generation Event.
- Consideration: Company issued 100,000 common shares to the Consultant. No cash payment disclosed.
- Unregistered Securities: Shares issued under Section 4(a)(2) and/or Rule 506(b) of Regulation D, relying on the private-offering exemption.
- Reg FD: A press release announcing the agreement was furnished as Exhibit 99.1 on 15 July 2025.
- Exhibits: 10.1 (Consulting Agreement), 99.1 (Press Release), 104 (Cover Page iXBRL file).
No financial performance metrics were provided in this filing. The transaction introduces crypto-related strategic initiatives while creating modest share dilution.
FAQ
What is the current stock price of 89Bio (ETNB)?
What is the market cap of 89Bio (ETNB)?
What is 89Bio, Inc. known for?
What therapeutic areas does 89Bio target?
What is pegozafermin and why is it important?
How is 89Bio advancing its clinical programs?
What differentiates the glycoPEGylated technology used by 89Bio?
Where is 89Bio headquartered and what is its background?
